ClassID:

20434

A61K31/5355 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines Non-condensed oxazines and containing further heterocyclic rings

Recent Application in this class:
#1
20260098047
2026-04-09

Anti-Giardial Compounds

#2
20260078114
2026-03-19

COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF

#3
20260035748
2026-02-05

METHODS FOR DETECTING AND TREATING IDIOPATHIC PULMONARY FIBROSIS

#4
20260021080
2026-01-22

PHARMACEUTICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING DEPRESSION AND OTHER DISORDERS

#5
20260015350
2026-01-15

AZAQUINAZOLINE PAN-KRAS INHIBITORS

#6
20260007665
2026-01-08

DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS

#7
20250375428
2025-12-11

CBL-B INHIBITORS AND ANTI-PD1/ANTI-PD-L1 FOR USE IN THE TREATMENT OF CANCER

#8
20250353825
2025-11-20

CANNABICYCLOL DERIVATIVES AND PREPARATION METHODS THEREOF

#9
20250352550
2025-11-20

SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE

#10
20250304571
2025-10-02

BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF

#11
20250213484
2025-07-03

A FREEZE-DRYING PROCESS FOR AN ADC

#12
20250179584
2025-06-05

PRECISION THERAPY FOR THE TREATMENT OF CANCER

#13
20250177581
2025-06-05

NTSR1-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY

#14
20250161315
2025-05-22

COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE

#15
20250161278
2025-05-22

CBL-B INHIBITOR, COMPOSITIONS COMPRISING A CBL-B INHIBITOR IN A METHOD OF TREATING A DISEASE ASSOCIATED WITH CELL PROLIFERATION

#16
20250152597
2025-05-15

LINEZOLID FORMULATIONS

#17
20250152596
2025-05-15

METHOD OF TREATING PAIN OR INTERSTITIAL CYSTITIS USING INDOLE COMPOUND

#18
20250109123
2025-04-03

COMBINATION THERAPY FOR TREATING CANCER

#19
20250059175
2025-02-20

Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals

#20
20250032473
2025-01-30

QUINOLINE DERIVATIVES

#21
20250026748
2025-01-23

N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA

#22
20250019373
2025-01-16

ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES

#23
20240423994
2024-12-26

TARGETING IMMUNE SUPPRESSION AFTER ATR INHIBITION

#24
20240408089
2024-12-12

DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS

#25
20240390355
2024-11-28

IRHOM2 INHIBITORS AND USES THEREOF

#26
20240382494
2024-11-21

THERAPEUTIC COMPOUNDS

#27
20240376073
2024-11-14

QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

#28
20240374602
2024-11-14

METHODS FOR TREATING NEUROGENERATIVE DISEASES

#29
20240368087
2024-11-07

SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF

#30
20240366623
2024-11-07

COMPOSITIONS FOR PREVENTING OR TREATING CHARCOT-MARIE-TOOTH DISEASE (CMT)

#31
20240342146
2024-10-17

TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY

#32
20240327393
2024-10-03

FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF

#33
20240308960
2024-09-19

PHENYL UREA DERIVATIVE

#34
20240307382
2024-09-19

MODULATORS OF THE INTEGRATED STRESS PATHWAY

#35
20240299438
2024-09-12

METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER ON BASIS OF ACTIVITY REGULATION MECHANISM OF DORMANT NEURAL STEM CELL

#36
20240285831
2024-08-29

METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION

#37
20240269156
2024-08-15

DISULFIDE CONTAINING THERAPEUTICS

#38
20240254118
2024-08-01

PRMT5 INHIBITORS AND USES THEREOF

#39
20240238303
2024-07-18

LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF

#40
20240228501
2024-07-11

IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE

#41
20240217959
2024-07-04

New (Homo)Piperidinyl Heterocycles as Sigma Ligands

#42
20240180899
2024-06-06

BENZAMIDE COMPOUNDS

#43
20240109868
2024-04-04

EP300/CBP MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF

#44
20240101671
2024-03-28

METHOD AND COMPOSITION FOR INDUCING TOLERANCE

#45
20240050435
2024-02-15

METHODS FOR TREATING CANCER

#46
20240041894
2024-02-08

3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

#47
20240033330
2024-02-01

TYPE I DIABETES THERAPY

#48
20230414608
2023-12-28

USE OF ATR AND CHK1 INHIBITOR COMPOUNDS

#49
20230381144
2023-11-30

COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN

#50
20230357265
2023-11-09

CDK Inhibitors And Their Use As Pharmaceuticals

#51
20230338369
2023-10-26

COMBINATION OF A PROTEASOME INHIBITOR AND A HDAC INHIBITOR AND ITS USE FOR THE TREATMENT OF GENETIC DISEASES LINKED TO A PROTEIN CONFORMATIONAL DISORDER

#52
20230310433
2023-10-05

COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

#53
20230285399
2023-09-14

Compound for the treatment and prophylaxis of a lipofuscin-associated disease and/or a disease associated with aged oxidized melanin

#54
20230201210
2023-06-29

COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE

#55
20230143410
2023-05-11

LINEZOLID FORMULATIONS

#56
20230090053
2023-03-23

Inhibitors of peptidylarginine deiminases

#57
20230087443
2023-03-23

ENHANCEMENT OF CD47 BLOCKADE THERAPY BY PROTEASOME INHIBITORS

#58
20230041518
2023-02-09

Quinoline derivatives

#59
20230021177
2023-01-19

1,2,4-triazine-4-amine derivatives

#60
20220395511
2022-12-15

COMPOSITIONS AND METHODS FOR INCREASING CELL SURFACE OXYTOCIN RECEPTOR (OXTR)

#61
20220323457
2022-10-13

Modulators of BCL6 proteolysis and associated methods of use

#62
20220281854
2022-09-08

COMBINATION THERAPY FOR TREATING CANCER

#63
20220273630
2022-09-01

Triple combination formulations for antiemetic therapy

#64
20220233524
2022-07-28

LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF

#65
20220226314
2022-07-21

Benzamide compounds

#66
20220220078
2022-07-14

Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

#67
20220218688
2022-07-14

PYRIDYLPYRIDONE COMPOUNDS

#68
20220153745
2022-05-19

DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS

#69
20220152027
2022-05-19

ANILINE-BASED WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR, AND PREPARATION METHOD AND USE THEREOF

#70
20220125894
2022-04-28

METHODS FOR TREATING INTRACRANIAL HEMORRHAGE AND ASSESSING EFFICACY

#71
20220089608
2022-03-24

CDK inhibitors and their use as pharmaceuticals

#72
20220047603
2022-02-17

SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES

#73
20220008427
2022-01-13

3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

#74
20220008418
2022-01-13

Aminoquinoline Derivatives and Uses Thereof

#75
20220002313
2022-01-06

HPK1 INHIBITORS AND METHODS OF USING SAME

#76
20210401840
2021-12-30

NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES

#77
20210380571
2021-12-09

POTASSIUM CHANNEL MODULATORS

#78
20210353619
2021-11-18

TREATMENT FOR VENETOCLAX-RESISTANT AND VENETOCLAX-SENSITIVE ACUTE MYELOID LEUKEMIA

#79
20210323928
2021-10-21

Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

#80
20210322380
2021-10-21

Combination drug

#81
20210260200
2021-08-26

Bifunctional molecules for targeting Rpn11

#82
20210253568
2021-08-19

AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS

#83
20210236487
2021-08-05

Methods and Compositions for Treatment of Cancer with PARP Inhibitors

#84
20210228591
2021-07-29

Compositions and methods of use thereof for treatment of proteinopathies

#85
20210205320
2021-07-08

Method of treating pain or interstitial cystitis using indole compound

#86
20210171653
2021-06-10

USE OF ISATUXIMAB FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

#87
20210169879
2021-06-10

Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

#88
20210121448
2021-04-29

Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors

#89
20210115065
2021-04-22

Compounds and compositions for the treatment of parasitic diseases

#90
20210113559
2021-04-22

Pyrimidine derivatives as PGE2 receptor modulators

#91
20210069199
2021-03-11

METHODS OF TREATING TRANSPLANT REJECTION

#92
20210053948
2021-02-25

Combination therapy for treating cancer

#93
20210025001
2021-01-28

Methods for Detecting and Treating Idiopathic Pulmonary Fibrosis

#94
20210015822
2021-01-21

Substituted amino triazoles useful as chitinase inhibitors

#95
20210009543
2021-01-14

Benzamide compounds

#96
20200377476
2020-12-03

Benzimidazole compounds and derivatives as EGFR inhibitors

#97
20200360396
2020-11-19

3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

#98
20200360374
2020-11-19

Dosing of inhibitor for treatment of cancers

#99
20200352952
2020-11-12

Linezolid formulations

#100
20200352937
2020-11-12

Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use

#101
20200345815
2020-11-05

Type I diabetes therapy

#102
20200345727
2020-11-05

MODULATORS OF THE INTEGRATED STRESS PATHWAY

#103
20200339605
2020-10-29

Benzamide compounds

#104
20200338071
2020-10-29

Benzamide compounds

#105
20200323863
2020-10-15

Anticancer treatment for uveal melanoma

#106
20200289496
2020-09-17

Pyridylpyridone compounds

#107
20200281932
2020-09-10

FORMULATIONS OF COPANLISIB

#108
20200268740
2020-08-27

EZH2 inhibitor combination therapies

#109
20200239458
2020-07-30

Inhibitors of protein kinases

#110
20200190104
2020-06-18

HPK1 inhibitors and methods of using same

#111
20200188368
2020-06-18

Triple combination formulations for antiemetic therapy

#112
20200181284
2020-06-11

EPIGENETIC INHIBITORS FOR SENSITIZING HEMATOLOGIC OR OTHER MALIGNANCIES TO GLUCOCORTICOID THERAPY

#113
20200155538
2020-05-21

Quinoline derivatives

#114
20200138796
2020-05-07

Compositions and methods for drug sensitization of parasites

#115
20200079727
2020-03-12

2-(substituted benzene matrix) aromatic formate FTO inhibitor, preparation method therefor, and applications thereof

#116
20200039960
2020-02-06

RORC2 INHIBITORS AND METHODS OF USE THEREOF

#117
20200016182
2020-01-16

STAT5a AND ITS FUNCTIONAL TUMOR SUPPRESSOR ANALOGS FOR TREATMENT OF MALIGNANCIES EXPRESSING NPM/ALK AND OTHER ONCOGENIC KINASES

#118
20200010474
2020-01-09

SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY

#119
20200002285
2020-01-02

Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

#120
20190388428
2019-12-26

A Pharmaceutical Composition Comprising An Oxazine Derivative And Its Use In The Treatment Or Prevention Of Alzheimer's Disease

#121
20190374547
2019-12-12

COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE

#122
20190352293
2019-11-21

Potassium channel modulators

#123
20190282581
2019-09-19

Intermediates useful in the synthesis of compounds as modulators of protein kinases

#124
20190276451
2019-09-12

FGFR4 inhibitor, preparation method therefor, and applications thereof

#125
20190269682
2019-09-05

Use of ATR and Chk1 inhibitor compounds

#126
20190262348
2019-08-29

3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

#127
20190262347
2019-08-29

COMPOSITION COMPRISING COMBINATION OF EPICATECHIN AND ANTI-CANCER COMPOUND

#128
20190256611
2019-08-22

Methods and pharmaceutical compositions for the treatment of lung cancer

#129
20190255082
2019-08-22

Enhancement of CD47 blockade therapy by proteasome inhibitors

#130
20190247392
2019-08-15

Aminoheteroaryl benzamides as kinase inhibitors

#131
20190224207
2019-07-25

Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same

#132
20190216792
2019-07-18

CDK1 inhibitors of acetyl chrysin mannich base derivatives, synthesis and use thereof

#133
20190167527
2019-06-06

TOPICAL ANTIMICROBIAL COMPOSITIONS AND METHODS OF FORMULATING THE SAME

#134
20190152980
2019-05-23

Substituted 4-methyl-pyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity

#135
20190144429
2019-05-16

RORC2 INHIBITORS AND METHODS OF USE THEREOF

#136
20190134050
2019-05-09

Dimeric compounds

#137
20190105324
2019-04-11

Substituted chromenones as modulators of protein kinases

#138
20190105323
2019-04-11

Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake

#139
20190092775
2019-03-28

2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides

#140
20190091226
2019-03-28

Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use

#141
20190062274
2019-02-28

Heterocyclic compound

#142
20190055199
2019-02-21

Biaryl derivative and medicine containing same

#143
20190047978
2019-02-14

1,2,4-triazine-4-amine derivatives

#144
20190046515
2019-02-14

AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS

#145
20190031658
2019-01-31

Benzamide and nicotinamide compounds and methods of using same

#146
20190016724
2019-01-17

DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS

#147
20180353504
2018-12-13

LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF

#148
20180318306
2018-11-08

METHODS OF TREATING TRANSPLANT REJECTION

#149
20180305367
2018-10-25

Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity

#150
20180298019
2018-10-18

Salt of EGFR inhibitor, crystalline form and uses thereof

#151
20180298012
2018-10-18

Octahydropyrrolopyrroles their preparation and use

#152
20180296546
2018-10-18

P38 MAP kinase inhibitors for wound healing

#153
20180282304
2018-10-04

RORC2 INHIBITORS AND METHODS OF USE THEREOF

#154
20180273488
2018-09-27

Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

#155
20180250305
2018-09-06

Nitric oxide-releasing prodrug molecule of substituted quinazolines

#156
20180215746
2018-08-02

Potassium channel modulators

#157
20180186783
2018-07-05

Inhibitors of protein kinases

#158
20180185343
2018-07-05

Methods of using indazole-3-carb oxamides and their use as Wnt/B-catenin signaling pathway inhibitors

#159
20180179221
2018-06-28

HPK1 inhibitors and methods of using same

#160
20180170874
2018-06-21

Heterocyclic compound

#161
20180117032
2018-05-03

Pharmacologically active compounds

#162
20180110783
2018-04-26

Substituted chromenones as modulators of protein kinases

#163
20180086736
2018-03-29

RORC2 INHIBITORS AND METHODS OF USE THEREOF

#164
20180037586
2018-02-08

Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity

#165
20180028532
2018-02-01

Aminoheteroaryl benzamides as kinase inhibitors

#166
20180000824
2018-01-04

Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor

#167
20180000779
2018-01-04

Combination drug

#168
20170368064
2017-12-28

Ink composition, printed matter and printing method

#169
20170348296
2017-12-07

Amido thiadiazole derivatives as NADPH oxidase inhibitors

#170
20170296548
2017-10-19

Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists

#171
20170291888
2017-10-12

1,2,4-triazine-4-amine derivatives

#172
20170267660
2017-09-21

Compounds and methods for kinase modulation, and indications therefor

#173
20170215424
2017-08-03

Noxious arthropod control agent containing amide compound

#174
20170209445
2017-07-27

KINASE INHIBITORS

#175
20170209441
2017-07-27

Aminoquinoline derivatives and uses thereof

#176
20170182038
2017-06-29

Aminoheteroaryl benzamides as kinase inhibitors

#177
20170173029
2017-06-22

3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

#178
20170166569
2017-06-15

Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto

#179
20170157134
2017-06-08

COMBINATION THERAPY

#180
20170152248
2017-06-01

Carbazole compounds useful as bromodomain inhibitors

#181
20170128463
2017-05-11

Rocuronium preparation with improved stability

#182
20170106008
2017-04-20

STAT5a and its functional tumor suppressor analogs for treatment of malignancies expressing NPM/ALK and other oncogenic kinases

#183
20170035772
2017-02-09

Methods for treating attention deficit hyperactivity disorder

#184
20170020886
2017-01-26

Amido-substituted azole compounds

#185
20170002013
2017-01-05

Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity

#186
20160354383
2016-12-08

Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use

#187
20160347748
2016-12-01

Benzamide and nicotinamide compounds and methods of using same

#188
20160304485
2016-10-20

Small molecule inhibitors of Mcl-1 and uses thereof

#189
20160303133
2016-10-20

TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS

#190
20160296514
2016-10-13

Pharmacologically active compounds

#191
20160272588
2016-09-22

USP7 inhibitor compounds and methods of use

#192
20160256463
2016-09-08

NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES

#193
20160244460
2016-08-25

Antiviral compounds

#194
20160237037
2016-08-18

Inhibitors of histone demethylases

#195
20160199383
2016-07-14

5-ALKYNYL-PYRIMIDINES

#196
20160193359
2016-07-07

NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF

#197
20160102096
2016-04-14

Compounds and methods for inhibiting histone demethylases

#198
20160039795
2016-02-11

Inhibitors

#199
20160016948
2016-01-21

Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants

#200
20160009701
2016-01-14

Carbazole compounds useful as bromodomain inhibitors

#201
20150374706
2015-12-31

NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES

#202
20150353524
2015-12-10

Pyridine compounds used as PI3 kinase inhibitors

#203
20150320752
2015-11-12

Compounds as modulators of protein kinases

#204
20150231138
2015-08-20

Sulfur-containing bicyclic compound

#205
20150150877
2015-06-04

NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

#206
20150133452
2015-05-14

Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase

#207
20150111883
2015-04-23

Substituted pyrimidine compounds and their use as SYK inhibitors

#208
20150094306
2015-04-02

Pyrrolopyridinone derivatives as TTX-S blockers

#209
20150094298
2015-04-02

Inhibitors of protein kinases

#210
20150038486
2015-02-05

Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy

#211
20150030618
2015-01-29

NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF

#212
20150023930
2015-01-22

Aminoquinoline derivatives and uses thereof

#213
20150011534
2015-01-08

Pyridazinone derivatives

#214
20150005276
2015-01-01

1,2,4-triazine-4-amine derivatives

#215
20140371224
2014-12-18

Compounds and compositions for treatment of breathing control disorders or diseases

#216
20140357599
2014-12-04

NOVEL UREA AND THIOUREA DERIVATIVES

#217
20140336173
2014-11-13

DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS

#218
20140256700
2014-09-11

Carbazole compounds useful as bromodomain inhibitors

#219
20140221367
2014-08-07

Pharmaceutical compounds

#220
20140179662
2014-06-26

Pharmaceutically active disubstituted triazine derivatives

#221
20140162999
2014-06-12

PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof

#222
20140128396
2014-05-08

Pyrimidinyl pyridazinone derivatives

#223
20140066623
2014-03-06

Ribosome structure and protein synthesis inhibitors

#224
20140065095
2014-03-06

Inhibitors

#225
20140038888
2014-02-06

Pharmaceutical combinations for the treatment of metabolic disorders

#226
20140031361
2014-01-30

Inhibitors of protein kinases

#227
20130289016
2013-10-31

Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy

#228
20130237539
2013-09-12

Compounds and Compositions for Treating Cancer

#229
20130230585
2013-09-05

Pharmaceutical compounds

#230
20130225566
2013-08-29

PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS

#231
20130225530
2013-08-29

WOGONIN FOR THE PREVENTION AND THERAPY OF CARDIAC HYPERTROPHY

#232
20130184261
2013-07-18

Pyridazinone derivatives

#233
20130184260
2013-07-18

Pyridazinone derivatives

#234
20130172331
2013-07-04

Oxazine derivatives and their use in the treatment of disease

#235
20130158000
2013-06-20

Disubstituted benzothienyl-pyrrolotriazines and uses thereof

#236
20130123254
2013-05-16

PHARMACEUTICALLY ACCEPTABLE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND THEIR METHODS OF IDENTIFICATION

#237
20130066055
2013-03-14

NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF

#238
20130065897
2013-03-14

COMPOUNDS, PREPARATION AND USES THEREOF

#239
20130029963
2013-01-31

1,2,4-triazine-4-amine derivatives

#240
20130023517
2013-01-24

Therapeutic methods employing substituted piperidines which are CCR3 antagonists

#241
20120295911
2012-11-22

Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases

#242
20120295908
2012-11-22

Pyrimidinyl pyridazinone derivatives

#243
20120289496
2012-11-15

Compounds as modulators of protein kinases

#244
20120277149
2012-11-01

PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS

#245
20120270804
2012-10-25

Methods for the treatment and prevention of ocular disorders

#246
20120157455
2012-06-21

Compounds And Compositions For Treating Cancer

#247
20120142647
2012-06-07

Compounds as respiratory stimulants for treatment of breathing control disorders or diseases

#248
20120129867
2012-05-24

Inhibitors of protein kinases

#249
20120107302
2012-05-03

Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use

#250
20120077869
2012-03-29

METHOD AND COMPOSITION USING A DUAL SPECIFICITY PROTEIN TYROSINE PHOSPHATASE AS AN ANTIMALARIAL DRUG TARGET

#251
20120028952
2012-02-02

5-alkynyl-pyrimidines

#252
20120010172
2012-01-12

Urea and thiourea derivatives

#253
20110218179
2011-09-08

Treatment of lupus nephritis using laquinimod

#254
20110172222
2011-07-14

Oxazolidinones for the Treatment of Inflammatory Conditions of the Gastrointestinal Tract

#255
20110124637
2011-05-26

Benzimidazoles and related analogs as sirtuin modulators

#256
20110098241
2011-04-28

RAPAMYCIN ANALOGS AS ANTI-CANCER AGENTS

#257
20110092501
2011-04-21

Inhibitors

#258
20110086043
2011-04-14

STAT5a and its functional tumor suppressor analogs for treatment of malignancies expressing NPM/ALK and other oncogenic kinases

#259
20110065701
2011-03-17

Pharmaceutical compounds

#260
20100312525
2010-12-09

Ribosome Structure and Protein Synthesis Inhibitors

#261
20100292198
2010-11-18

Cyclic progestin regimens and kits

#262
20100261687
2010-10-14

Substituted piperidines as CCR3 antagonists

#263
20100249099
2010-09-30

Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy

#264
20100234366
2010-09-16

Use of Strobilurins for the Treatment of Disorders of Iron Metabolism

#265
20100234354
2010-09-16

Pyridazinone derivatives

#266
20100204253
2010-08-12

Ribosome structure and protein synthesis inhibitors

#267
20100197690
2010-08-05

Pyrimidinyl pyridazinone derivatives

#268
20100160301
2010-06-24

MICROANGIOPATHY TREATMENT AND PREVENTION

#269
20100131258
2010-05-27

Method for identifying protein synthesis inhibitors by ribosome structure

#270
20100125065
2010-05-20

Carboline derivatives useful in the inhibition of angiogenesis

#271
20100105687
2010-04-29

METHODS FOR TREATING COGNITIVE DISORDERS USING 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS

#272
20100062975
2010-03-11

Method for the treatment and prevention of ocular disorders

#273
20100009987
2010-01-14

AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK

#274
20090318407
2009-12-24

Inhibitors of protein kinases

#275
20090318334
2009-12-24

Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease

#276
20090232828
2009-09-17

Methods of using IGFIR and ABL kinase modulators

#277
20090227618
2009-09-10

Carboline derivatives useful in the inhibition of angiogenesis

#278
20090221569
2009-09-03

Use of LHRH antagonists for intermittent treatments

#279
20080299132
2008-12-04

Synergistic compositions for treating HIV-1

#280
20080194549
2008-08-14

Organic compounds

#281
20080182806
2008-07-31

USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS

#282
20080161355
2008-07-03

Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents

#283
20080103135
2008-05-01

Phenylalkynes

#284
20080096876
2008-04-24

Phenylalkynes

#285
20080090819
2008-04-17

Derivatives of [6,7-dihydro-5-imidazo[1,2-α]imidazole-3-sulfonylamino]-propionamide

#286
20080076768
2008-03-27

Pharmaceutical compounds

#287
20080033002
2008-02-07

Modulators of muscarinic receptors

#288
20080003214
2008-01-03

Medicaments Comprising Carbonyl Compounds, And The Use Thereof

#289
20070281962
2007-12-06

Carboline Derivatives Useful in the Inhibition of Angiogenesis

#290
20070225293
2007-09-27

Use of C-Kit Inhibitors for Treating Fibrosis

#291
20070225287
2007-09-27

Substituted Arylpyrazines

#292
20070149572
2007-06-28

Method of inhibiting FLT3 kinase

#293
20070105959
2007-05-10

Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient

#294
20070072837
2007-03-29

Phenylalkynes

#295
20070032491
2007-02-08

Combination of a glycine/nmda antagonist and a tachykinin nk-1 receptor antagonist for use in the treatment of neurodegeneration

#296
20060281813
2006-12-14

Methods of treating hyperproliferative cell disorders

#297
20060258859
2006-11-16

Phenylalkynes

#298
20060136146
2006-06-22

MODULATORS OF RIBOSOMAL FUNCTION AND IDENTIFICATION THEREOF

#299
20060135529
2006-06-22

Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof

#300
20060009428
2006-01-12

Cyclic progestin regimens and kits